BOTHELL — Seattle Genetics can resume all testing on an experimental drug to treat an aggressive form of cancer known as acute myeloid leukemia.
The company had paused a couple of small-scale tests of vadastuximab talirine (SGN-CD33A) in late December due to concerns that the drug might have caused liver damage in six people, four of whom died. Tests with larger patient pools were not affected by the halt.
The U.S. Food and Drug Administration has cleared the tests to proceed, the Bothell-based company said Monday.
Talk to us
- You can tell us about news and ask us about our journalism by emailing firstname.lastname@example.org or by calling 425-339-3428.
- If you have an opinion you wish to share for publication, send a letter to the editor to email@example.com or by regular mail to The Daily Herald, Letters, P.O. Box 930, Everett, WA 98206.
- More contact information is here.